Outcomes, costs and cost-effectiveness of treating hepatitis C with direct acting antivirals.
about
Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study.Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.Real-World Sustained Virologic Response Rates of Sofosbuvir-Containing Regimens in Patients Coinfected With Hepatitis C and HIV.Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection.Patch-Clamp Study of Hepatitis C p7 Channels Reveals Genotype-Specific Sensitivity to Inhibitors.The cost of successful antiviral therapy in hepatitis C patients: a comparison of IFN-free versus IFN-based regimens at an individual patient level in Australia.
P2860
Outcomes, costs and cost-effectiveness of treating hepatitis C with direct acting antivirals.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Outcomes, costs and cost-effec ...... with direct acting antivirals.
@en
type
label
Outcomes, costs and cost-effec ...... with direct acting antivirals.
@en
prefLabel
Outcomes, costs and cost-effec ...... with direct acting antivirals.
@en
P2093
P2860
P356
P1476
Outcomes, costs and cost-effec ...... with direct acting antivirals.
@en
P2093
Christian Krauth
Jona T Stahmeyer
Siegbert Rossol
P2860
P356
10.2217/CER.15.13
P577
2015-05-11T00:00:00Z